Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years

Hong, Ji Hyung; Ha, Kyung Sun; Jung, Yun Hwa; Won, Hye Sung; An, Ho Jung; Lee, Guk Jin; Kang, Dong Hoon; Park, Kang Hyun; Park, Sarah; Byun, Jae Ho; Suh, Young Jin; Kim, Jeong Soo; Park, Woo Chan; Jung, Sang Seol; Park, Il Young; Chung, Sung-Chong; Woo, In Sook

doi:10.4143/crt.2015.410

Cited by 44 publications

(41 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of male breast cancer is less than 1 case per 100,000 men per year, globally. In approximately three-quarters of malignant cases and nearly all benign cases, male patients present with a palpable mass [3, 4]. …”

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions

et al. 2019

View full text Add to dashboard Cite

Objective: Differentiation between gynecomastia, a common cause of male breast enlargement, and breast cancer is crucial for appropriate management. Fine-needle aspiration biopsy has been shown to be sensitive and specific in assessing female breast lesions, comparable to core needle biopsy. Few such studies have been conducted in men. We assessed its diagnostic value in a male patient cohort. Study Design: Men who underwent fine-needle aspiration (FNA) for palpable breast lesions at Massachusetts General Hospital from January 2007 to December 2016 were evaluated. Clinical data, radiographic findings, and cytologic diagnoses of 74 breast FNA from 71 men were reviewed. Breast aspirates were classified as nondiagnostic, benign, atypical, suspicious for malignancy, or malignant. Histology was obtained in 37 cases, and clinical and radiological data were used as follow-up in 37 patients. Results: Most FNA biopsies (73%) were performed by cytopathologists, and 93.2% of the breast FNA in men were adequate; 58% showed benign processes, mostly gynecomastia (n = 22), and 28.4% (n = 21) were malignant, most often ductal carcinoma. No false-positive cytologies were obtained, and there was 1 false-negative cytology. In our study, FNA of palpable male breast lesions was 95.8% sensitive and 100% specific. Conclusions: FNA allows sensitive, specific, and safe evaluation and diagnosis of palpable male breast lesions.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A relevant role in MBC pathogenesis is played by genetic risk factors; many studies showed that 15-20% of male patients with BC have a family history of breast cancer, a higher percentage than what observed in women with BC (7%) [14][15][16]. Accordingly, among our patients was recorded a high percentage of positive family history of BC, i.e., 42.3%.…”

Section: Discussionmentioning

confidence: 40%

Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up

Pellini¹,

Mirandola²,

Granuzzo³

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

Introduction. Male breast cancer (MBC) is a rare disease, whose main risk factor is genetic vulnerability. Despite care of men with MBC is modeled on care of women, men’s experiences with the disease and concerns related to the status of genetic mutation carrier are unique. So far, little is known concerning the psychological impact in BRCA1/2 testing, especially with regard to specific subset of individuals, such as male subjects and the elderly. Methods. We assessed self-reported anxiety and depression levels in 26 male subjects presenting at Unit of Breast Surgery in Breast Unit of AOUI Verona (MBC patients, n = 7; high-risk unaffected subjects, n = 19). We specifically examined the scores obtained by these subjects in the HADS questionnaire administered before and 6 months after the genetic testing for BRCA gene mutations. Results. Among the 17 unaffected men tested, 7 (41%) received a positive test (either BRCA1 or BRCA2 pathogenic variant) and 10 (59%) a negative test. Of the 9 MBC patients tested, only one subject received a positive test result. No significant differences were observed in mean scores, mean change from baseline to follow-up, either for those with T+ or T− test results. Discussion. Genetic testing for BRCA1/2 mutation was not associated in our sample with increased level of psychological distress as measured with HADS in a short-term evaluation.

show abstract

“…In a multicentre study of 50 Korean MBC patients, 42 had known receptor status and 38 (91%) were ER +ve (Hong et al 2016). Use of adjuvant endocrine therapy improved OS in patients with ER+ve tumours (median survival 8.5 years vs 4.2 years for those not given endocrine treatment).…”

Section: Adjuvant Treatmentmentioning

confidence: 99%

The endocrinology of male breast cancer

Fentiman¹

2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

Male breast cancer (MBC) is a rare disease but, as a result of epidemiological collaborations, there is now greater clarity concerning endocrine risk factors. The significant rise in global age-standardised mean BMI in men is likely to lead to increases in incidence of maturity-onset diabetes and MBC. The metabolic changes accompanying obesity decrease androgens and sex hormone-binding globulin (SHBG), thereby increasing available oestrogens. The higher rates of MBC in North and Equatorial Africa are largely due to liver damage from endemic bilharziasis and hepatitis B causing elevated oestradiol (E) levels from hepatic conversion of androgen. Klinefelter's syndrome (XXY) is associated with a 50-fold increase in incidence of MBC compared with XY males, and this is the most pronounced evidence for testicular malfunction amplifying risk. Delay in presentation means that up to 40% of cases have stage III or stage IV disease at diagnosis. No randomised controlled trials have been reported on endocrine treatment of advanced disease or adjuvant/neoadjuvant therapy following or preceding surgery. Tamoxifen is the most effective endocrine therapy, but side effects can lead to non-compliance in a substantial number of men. Aromatase inhibitors are less effective because they do not inhibit testicular oestrogen production. There is an urgent need for collaborative trials to provide an evidence base for the most effective endocrine and least toxic therapies for men with breast cancer.

show abstract

Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years

Cited by 44 publications

References 23 publications

Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions

Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions

Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up

The endocrinology of male breast cancer

Contact Info

Product

Resources

About